Boyer; Jose L.

Patent Applications and Registrations

Patent applications and USPTO patent grants for Boyer; Jose L..The latest application filed is for "process for the preparation of sterile ophthalmic aqueous fluticasone propionate form a nanocrystals suspensions".

Company Profile

0.18.23

Boyer; Jose L. - Chapel Hill NC

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Process for the preparation of sterile ophthalmic aqueous fluticasone propionate form a nanocrystals suspensions Grant 11,406,596 - Bukowski , et al. August 9, 2	2022-08-09
Process For The Preparation Of Sterile Ophthalmic Aqueous Fluticasone Propionate Form A Nanocrystals Suspensions App 20220241296 - BUKOWSKI; Jean-Michel ; et al.	2022-08-04
Process For The Preparation Of Sterile Ophthalmic Aqueous Fluticasone Propionate Form A Nanocrystals Suspensions App 20210023001 - BUKOWSKI; Jean-Michel ; et al.	2021-01-28
Novel Mucolytic Agents App 20150307530 - JOHNSON; Michael R. ; et al.	2015-10-29
Method For Treating Cardiovascular Diseases Using Rho Kinase Inhibitor Compounds App 20130172324 - LAMPE; John W. ; et al.	2013-07-04
Method of treating blepharitis Grant 8,349,806 - Brubaker , et al. January 8, 2	2013-01-08
Method for treating cystic fibrosis Grant 8,168,597 - Kellerman , et al. May 1, 2	2012-05-01
P2Y.sub.6 receptor agonists for treating lung diseases Grant 8,158,776 - Boyer , et al. April 17, 2	2012-04-17
Non-nucleotide composition for inhibiting platelet aggregation Grant 7,943,760 - Plourde, Jr. , et al. May 17, 2	2011-05-17
P2y6 Receptor Agonists For Treating Lung Diseases App 20110054163 - Boyer; Jose L. ; et al.	2011-03-03
P2Y6 receptor agonists for treating lung diseases Grant 7,851,456 - Boyer , et al. December 14, 2	2010-12-14
Non-nucleotide Composition For Inhibiting Platelet Aggregation App 20100197913 - Plourde, JR.; Robert ; et al.	2010-08-05
Drug-eluting stents coated with non-nucleotide P2Y.sub.12 receptor antagonist compound Grant 7,749,981 - Boyer , et al. July 6, 2	2010-07-06
Method For Treating Inflammatory Conditions App 20100160250 - Douglass, III; James G. ; et al.	2010-06-24
Method For Treating Cystic Fibrosis App 20100099635 - Kellerman; Donald J. ; et al.	2010-04-22
Method Of Treating Blepharitis App 20100022465 - Brubaker; Kurt E. ; et al.	2010-01-28
Method For Treating Cardiovascular Diseases Using Rho Kinase Inhibitor Compounds App 20100008968 - Lampe; John W. ; et al.	2010-01-14
Drug-eluting stents coated with P2Y.sub.12 receptor antagonist compound Grant 7,618,949 - Boyer , et al. November 17, 2	2009-11-17
Degradation-resistant mononucleoside phosphate compounds Grant 7,612,047 - Douglass, III , et al. November 3, 2	2009-11-03
Non-nucleotide composition and method for inhibiting platelet aggregation Grant 7,592,445 - Plourde, Jr. , et al. September 22, 2	2009-09-22
Method Of Treating Pulmonary Edema Or Pulmonary Inflammation App 20090098064 - Navratil; Tomas ; et al.	2009-04-16
Degradation-resistant Mononucleoside Phosphate Compounds App 20090076256 - Douglass, III; James G. ; et al.	2009-03-19
Drug-eluting Stents Coated With P2y12 Receptor Antagonist Compound App 20080287671 - Boyer; Jose L. ; et al.	2008-11-20
Drug-eluting stents coated with P2Y.sub.12 receptor antagonist compound Grant 7,452,870 - Boyer , et al. November 18, 2	2008-11-18
Degradation-resistant mononucleoside phosphate compounds Grant 7,435,724 - Douglass, III , et al. October 14, 2	2008-10-14
Non-nucleotide compositions and method for inhibiting platelet aggregation Grant 7,368,438 - Plourde, Jr. , et al. May 6, 2	2008-05-06
Non-nucleotide Composition And Method For Inhibiting Platelet Aggregation App 20080103304 - Plourde; Robert JR. ; et al.	2008-05-01
Non-nucleotide composition and method for inhibiting platelet aggregation Grant 7,335,648 - Plourde, Jr. , et al. February 26, 2	2008-02-26
Degradation-resistant mononucleoside phosphate compounds App 20070244068 - Douglass; James G. III ; et al.	2007-10-18
P2Y6 receptor agonists for treating lung diseases App 20070015726 - Boyer; Jose L. ; et al.	2007-01-18
Composition and method for inhibiting platelet aggregation Grant 7,132,408 - Boyer , et al. November 7, 2	2006-11-07
Composition and method for inhibiting platelet aggregation Grant 7,101,860 - Boyer , et al. September 5, 2	2006-09-05
Drug-eluting stents coated with P2Y12 receptor antagonist compound App 20060122143 - Boyer; Jose L. ; et al.	2006-06-08
Drug-eluting stents coated with non-nucleotide P2Y12 receptor antagonist compound App 20060121086 - Boyer; Jose L. ; et al.	2006-06-08
Composition and method for inhibiting platelet aggregation Grant 7,018,985 - Boyer , et al. March 28, 2	2006-03-28
Non-nucleotide composition and method for inhibiting platelet aggregation App 20050267134 - Plourde,, Robert JR. ; et al.	2005-12-01
Compositions for the treatment of glaucoma or ocular hypertension App 20050130931 - Boyer, Jose L. ; et al.	2005-06-16
Compositions and methods for the treatment of glaucoma or ocular hypertension Grant 6,897,201 - Boyer , et al. May 24, 2	2005-05-24
Composition and method for inhibiting platelet aggregation App 20040220133 - Boyer, Jose L. ; et al.	2004-11-04
Compositions and methods for the treatment of glaucoma or ocular hypertension App 20020128224 - Boyer, Jose L. ; et al.	2002-09-12
Composition and method for inhibiting platelet aggregation App 20020052337 - Boyer, Jose L. ; et al.	2002-05-02

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.